Isomorphic Labs Raises $5B to Take AI-Designed Drugs Toward Clinical Trials

A scientist in a white protective suit, yellow gloves and safety goggles holding up a flask of blue liquid against a pink and purple background

Photo: Hippopx (public domain). Illustrative image.

What happened. Isomorphic Labs announced an oversubscribed $5 billion Series C on 17 November 2026, one of the largest biotech funding rounds ever raised. The round was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz and other new investors joining, and continued significant investment from Alphabet. All existing investors returned, including Thrive, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. The company is a DeepMind spin-out founded in 2021, led by chief executive Demis Hassabis.

What the money is for. The proceeds will scale Isomorphic’s IsoDDE drug-design engine — a suite of simulation models spanning therapeutic areas and drug modalities — advance its therapeutic pipeline, and build AI-led bioengineering and clinical infrastructure. The release claims “positive preclinical results” in oncology and immunology. That claim should be read carefully: no drug candidate is named, no data is published, and no trial start date is given. The round is a vote on the platform, not on a drug that has yet been tested in people. No valuation was disclosed in the release; the roughly $50 billion figure circulating in press coverage is a Bloomberg report, not the company’s number.

Why this round is different. Five billion dollars is not a normal Series C — it is a statement that AI drug discovery has moved from the research phase to the industrial phase. The investor list tells the story: venture firms, sovereign funds and Alphabet itself, all betting that the bottleneck in drug discovery is now compute and simulation rather than wet-lab throughput. Isomorphic sits at the centre of that bet because it inherits DeepMind’s structural biology work — the same lineage as AlphaGenome 2, DeepMind’s DNA model — and because its engine is designed to design drugs rather than merely screen them. The contrast with the other big round of the day is instructive: Genesis AI raised $500M for general-purpose robots at a $3.5B valuation; Isomorphic raised ten times as much for a platform whose first clinical proof is still ahead of it.

Why it matters. If IsoDDE works as claimed, the cost and time of getting a drug candidate to the clinic could fall sharply — and the first company to prove an AI-designed drug in human trials will reset the economics of the whole pharmaceutical industry. The $5 billion buys Isomorphic the runway to try. The honest measure of this round will not be the valuation but the first clinical readout, which is still years away.

Sources

  • Isomorphic Labs
  • Series C
  • AI drug discovery
  • DeepMind
  • Demis Hassabis

Related articles